Uplarafenib

Cat. No.:	HY-148059		
CAS No.:	1425485-87	-5	
Molecular Formula:	C ₂₂ H ₂₁ F ₃ N ₄ O	₄ S	
Molecular Weight:	494.49		
Target:	Raf		
Pathway:	MAPK/ERK I	Pathway	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro


$\mathsf{DMSO}:100\ \mathsf{mg/mL}$ (202.23 mM; ultrasonic and warming and heat to $60^\circ\mathsf{C})$

Preparing Stock Solutions	Solvent Mass Concentration	Solvent 1 mg		10 mg
	1 mM	2.0223 mL	10.1114 mL	20.2229 mL
	5 mM	0.4045 mL	2.0223 mL	4.0446 mL
	10 mM	0.2022 mL	1.0111 mL	2.0223 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACT	Ινιτγ	
Description	Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC ₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity ^[1] .	
IC ₅₀ & Target	BRAF-V600E < 50 nM (IC ₅₀)	Braf 50-100 nM (IC ₅₀)
In Vitro	Uplarafenib (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E ^[1] . Uplarafenib shows an IC ₅₀ between 50 and 100 nM against BRAF, less than 50 nM against BRAF V600E ^[1] . Uplarafenib (72 h) inhibits A375 and SK-MEL-28 cells growth but not CHL-1 and SK-MEL-31 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	A375, SK-MEL-28, SK-MEL-31 and CHL-1
	Concentration:	

Product Data Sheet



	T
Incubation Time:	72 h
Result:	Showed inhibition with IC ₅₀ s less than 500 nM against A375 and SK-MEL-28 cells, and showed no inhibition against CHL-1 and SK-MEL-31.

REFERENCES

[1]. Yong-Liang Zhu, et al. Certain Chemical Entities, Compositions, and Methods. Patent US20130053384 A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA